An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma.

Trial Profile

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top